MannKind submits Afresa NDA

MannKind (NASDAQ:MNKD) submitted an NDA to FDA for Afresa to treat Type I and Type II diabetes. Afresa is a dry powder formulation of insulin plus an inhaler. MannKind added $0.04 to $3.10 on Monday. ...